Cue Biopharma, Inc.
CUE
$0.7684
$0.01822.43%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.58M | 3.34M | 2.66M | 1.72M | 1.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.58M | 3.34M | 2.66M | 1.72M | 1.82M |
| Cost of Revenue | 9.78M | 8.48M | 9.53M | 10.20M | 13.49M |
| Gross Profit | -8.21M | -5.15M | -6.87M | -8.48M | -11.67M |
| SG&A Expenses | 1.42M | 3.77M | 3.51M | 4.19M | 2.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.21M | 12.25M | 13.04M | 14.39M | 15.50M |
| Operating Income | -9.63M | -8.91M | -10.38M | -12.67M | -13.68M |
| Income Before Tax | -9.50M | -8.66M | -10.17M | -12.35M | -13.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.50M | -8.66M | -10.17M | -12.35M | -13.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.50M | -8.66M | -10.17M | -12.35M | -13.43M |
| EBIT | -9.63M | -8.91M | -10.38M | -12.67M | -13.68M |
| EBITDA | -9.53M | -8.81M | -10.28M | -12.57M | -13.56M |
| EPS Basic | -0.13 | -0.17 | -0.20 | -0.25 | -0.28 |
| Normalized Basic EPS | -0.08 | -0.11 | -0.13 | -0.16 | -0.18 |
| EPS Diluted | -0.13 | -0.17 | -0.20 | -0.25 | -0.28 |
| Normalized Diluted EPS | -0.08 | -0.11 | -0.13 | -0.16 | -0.18 |
| Average Basic Shares Outstanding | 74.24M | 51.23M | 50.17M | 49.47M | 47.20M |
| Average Diluted Shares Outstanding | 74.24M | 51.23M | 50.17M | 49.47M | 47.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |